Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pan-Cancer Pharmacogenomic Analysis of Patient-Derived Tumor Cells Using Clinically Relevant Drug Exposures.

Molecular cancer therapeutics - 5 Sept 2023

Chang Stephen H, Ice Ryan J, Chen Michelle, Sidorov Maxim, Woo Rinette W L, Rodriguez-Brotons Aida, Jian Damon, Kim Han Kyul, Kim Angela, Stone David E, Nazarian Ari, Oh Alyssia, Tranah Gregory J, Nosrati Mehdi, de Semir David, Dar Altaf A, Desprez Pierre-Yves, Kashani-Sabet Mohammed, Soroceanu Liliana, McAllister Sean D

Abstract excerpt

As a result of tumor heterogeneity and solid cancers harboring multiple molecular defects, precision medicine platforms in oncology are most effective when both genetic and pharmacologic determinants of a tumor are evaluated. Expandable patient-derived xenograft (PDX) mouse tumor and corresponding PDX culture (PDXC) models recapitulate many of the biological and genetic characteristics of the original patient...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Mice

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Neoplasms

Share to Pharmacogenomic Testing

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 37440705
DOI: 10.1158/1535-7163.MCT-22-0486

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pan-Cancer Pharmacogenomic Analysis of Patient-Derived Tumor Cells Using Clinically Relevant Drug Exposures.PMID 37440705Read ↗

Systematic functional drug testing in patient-derived models reveals ex vivo sensitivities associated with clinical outcome in rare solid tumorsSemantic proximity Read ↗

A Landscape of Pharmacogenomic Interactions in Cancer.Semantic proximity Read ↗

Methods and resources to access mutation-dependent effects on cancer drug treatment.Semantic proximity Read ↗

Pharmacogenomic discovery of genetically targeted cancer therapies optimized against clinical outcomesSemantic proximity Read ↗

Systematic pan-cancer analysis of mutation-treatment interactions using large real-world clinicogenomics data.Semantic proximity Read ↗

Somatic mutation patterns and compound response in cancers.Semantic proximity Read ↗

Characterizing mutation-treatment effects using clinico-genomics data of 78,287 patients with 20 types of cancers.Semantic proximity Read ↗

Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapySemantic proximity Read ↗

Integrative omics analyses broaden treatment targets in human cancer.Semantic proximity Read ↗

Data Mining Approaches for Genomic Biomarker Development: Applications Using Drug Screening Data from the Cancer Genome Project and the Cancer Cell Line Encyclopedia.Semantic proximity Read ↗

Probabilistic modeling of personalized drug combinations from integrated chemical screen and molecular data in sarcomaSemantic proximity Read ↗

Integrated Patient-Derived Models Delineate Individualized Therapeutic Vulnerabilities of Pancreatic CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.